2.58
-0.77%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Elicera Therapeutics
Its shares trade on Nasdaq Stockholm under the ticker ELIC.ST. It has been listed since 11 June 2021. In the fiscal year to 31 December 2024, it reported revenue of SEK 7.1m and a net loss of SEK 16.1m. At that date it held total assets of SEK 27.6m and shareholders' equity of SEK 20.8m.
Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jun 2021
- Website
- elicera.com ↗
Leadership
Pay as last reported
- Jamal El-MoslehChief Executive Officer, since 2014
- Rolf Ingvar Karlsson LenartChief Financial Officer, since 2021
- Di Yu, PhDDevelopment Director, since 2014
- Magnus EssandDirector & Head-Research, since 2014
- Eva Agneta EdbergChairman, since 2020
- Karin Hoogendoorn, PhDIndependent Director, since 2021
- Christina Elisabeth Herder, PhD, EMBAIndependent Director, since 2020
- Margareth Jorvid, MBAIndependent Director, since 2020
- Jan Gustaf ZetterbergIndependent Director, since 2020
- Magnus EssandDirector & Head-Research, since 2014
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Elicera Therapeutics AB develops next-generation cell and gene therapies for immune-based cancer treatments.
- The firm possesses the fully developed iTANK platform technology for immune strengthening.
- Two drug candidates are in the oncolytic virus field and two in CAR T-cell treatments.
Weaknesses
- The company operates as a clinical stage immuno-oncology company with limited commercial products.
- ELC-100 is currently in a clinical phase I/II trial for neuroendocrine tumors.
- ELC-301 requires planning and implementation of a clinical phase I/II study for B-cell lymphoma.
Opportunities
- The Swedish Cancer Society granted support for the planning of the ELC-301 clinical study.
- Uppsala University sponsors the clinical phase I/II trial for the ELC-100 oncolytic virus.
- Immune-based cancer treatments represent a growing segment for next-generation cell and gene therapies.
Threats
- Clinical trials for ELC-100 and ELC-301 face inherent risks of regulatory delays.
- Competitors in the biotechnology sector may develop superior oncolytic virus or CAR T-cell therapies.
- Failure in phase I/II trials could halt development of the ELC-100 and ELC-301 candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.